Calendar of CURE/Yale BioHaven seminars for Fall 2010 now available. more
9/14
8:45 am - 6:00 pm
Ubifrance, the French Agency for international business development, cordially invites CURE members to this year's second French Biotech Tour, which aims to connect French and American Biotech companies specialized in neuroscience, inflammation, and auto-immune diseases. Philadelphia, PA. more
9/16
6:00 pm - 7:30 pm
CURE/Yale BioHaven presents Al Mann: 'Creating a successful medical device enterprise.' Hope Auditorium, Yale University, 315 Cedar Street, New Haven. more
10/5
Deadline for nominations for the Lemelson-MIT prize, awarded to an outstanding mid-career inventor who has developed a patented product or process of significant value to society. more
10/14
4:00 pm - 7:00 pm
Hartford Hospital Research Symposium. 'Personalized Medicine and Genomics: The Future is Now.' RSVP by 10/1 to 860.545.5620. Heublein Hall, Education & Resource Center, Hartford Hospital, Hudson Street, Hartford. more
10/27
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Cobalt Therapeutics. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Biodel Inc. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
12/7
5:30 pm - 7:30 pm
CURE Holiday Party. Café George, 300 George Street, New Haven. Watch for details.


CGI Pharmaceuticals, Inc.
 36 East Industrial Road
Branford, CT 06405

Phone: 203-315-1222
Fax: 203-488-7838
Website: http://www.cellulargenomics.com

General Information
CGI Pharmaceuticals, Inc. (CGI) is a drug discovery and development company that is dedicated to developing breakthrough kinase inhibitor therapeutics for large unmet medical needs across a broad range of diseases. CGI's lead current drug discovery and development programs address compelling, well-validated targets for major clinical indications in cancer, angiogenesis, and allergic/autoimmune/inflammatory diseases. Promising drug candidates representing potential breakthrough, first-in-class therapeutics, have been developed in two rapidly advancing programs. CGI's powerful HALO chemistry platform represents a highly effective system for the rapid advancement of drug discovery programs from hit identificat8ion through lead optimization and into clinical development. Likewise, CGI's proprietary chemical genetics technologies have multiple applications throughout all phases of the drug discovery process and enhance CGI's state-of-the-art drug discovery and development capabilities.

Back

Designed by BlausenLisi
Copyright © 2006 Connecticut United for Research Excellence, Inc.